35 results about "Endometrium thickness" patented technology

The present invention relates to a progesterone eutectic, which is formed from an active ingredient progesterone and a eutectic formation, wherein the eutectic formation is selected from isophthalic acid, 4-formylphenylboronic acid or 3-nitrophthalic acid. The invention also relates to a preparation method of the progesterone eutectic and an application of the progesterone eutectic in increasing the thickness of endometrium, improving the solubility of progesterone or increasing the penetration rate of progesterone.

The invention discloses traditional Chinese medicine for treating thin endometrium. The traditional Chinese medicine is mainly prepared from radix codonopsis, semen euryales, cornu cervi degelatinatum, fructus psoraleae, herba cistanches, rhizoma dioscoreae, pulp of cornus, radix salviae miltiorrhizae, caulis spatholobi, common ginger, trogopterus dung processed with wine and radix glycyrrhizae preparata. The formula composed of raw material medicine tonifies the kidney, activates blood, replenishes essence and cultivates cells, therefore, thickness of endometrium of females is enhanced, the menstrual blood volume is increased, capability of gestating babies of females is improved, and clinical treatment efficiency of the traditional Chinese medicine is 97.78%.

The invention discloses the application of FoxM1 in the preparation of reagents for diagnosing and treating intrauterine adhesion diseases. Application of FoxM1 as a detection target in the preparation of diagnostic reagents for intrauterine adhesions. Application of FoxM1 in preparation of medicine for treating diseases caused by uterine fibrosis. The present invention finds through experiments that the expression of FoxM1 in the endometrial tissue of patients with intrauterine adhesions is significantly reduced, especially the reduction of epithelial cells is the most significant, and the expression level of FoxM1 has a certain positive correlation with the thickness of endometrium in patients with intrauterine adhesions. The ROC plot showed that FoxM1 had good diagnostic value for intrauterine adhesions. In vitro results showed that the expression level of FoxM1 was also significantly decreased in TGFβ1-induced epithelial cell fibrosis. Therefore, FoxM1 may play an important role in the detection and treatment of intrauterine adhesions, and can be used in the clinical diagnosis and treatment of intrauterine adhesions.

The invention relates to a traditional Chinese medicine for treating functional uterine bleeding. If traditional Chinese medicines, which are commonly used in the field of functional uterine bleeding and comprise saururus chinensis, red cockscomb and caulis spatholobi, are singly used, only a slight hematostatic function is achieved and obvious curative effect in treating metrorrhagia is not achieved. If two medicines are used together, only a certain curative effect on postpartum flooding is achieved, but is not obvious. The traditional Chinese medicine for treating functional uterine bleeding is prepared from the following components in parts by weight: 14 to 30 parts of saururus chinensis, 10 to 20 parts of red cockscomb and 9 to 20 parts of caulis spatholobi. The saururus chinensis, the red cockscomb and the caulis spatholobi are used together, so the traditional Chinese medicine for treating functional uterine bleeding has anti-inflammatory and hemostatic effects, can reduce the thickness of endometrium and reduce bleeding amount, can also promote follicle proliferation and maturity, and has a good curative effect on anovulatory metrorrhagia. The secrete prescription has good curative effects on postpartum flooding and anovulatory metrorrhagia, and can cure the metrorrhagia temporarily and permanently by finally adjusting and improving the endocrine function of an organism.

The invention discloses a traditional Chinese medicine composition capable of treating menstrual flow and infertility caused by thin endometrium and a preparation method thereof. 1~6 parts, 1~9 parts of cornus, 1~6 parts of fried white peony, 0.5~3 parts of fried angelica, 1~9 parts of Chuanxiong, 1.5~9 parts of Suanzaoren, 1~9 parts of Anemarrhena, cloud Made from 1-6 parts of Poria cocos, 1-6 parts of fried Codonopsis pilosula, and 1-12 parts of fried Atractylodes macrocephala. The present invention screens and obtains the prescription through a large number of clinical studies, and the research results show that the Chinese medicine compound can effectively improve the symptoms of less menstrual flow and infertility of the kidney yin deficiency type, increase menstrual flow, and promote endometrial hyperplasia and follicular growth in the late menstrual period. Develop and improve serum E2 and LH levels during ovulation, improve E2 and P levels in the mid-luteal phase, increase the thickness of the endometrium in the mid-luteal phase, increase the volume of the endometrium, and enrich the subendometrial blood perfusion in the mid-luteal phase, thereby increasing the endometrial volume Receptivity, promote embryo implantation, and no toxic side effects, safe and reliable medication.

The invention discloses novel application of a medicinal composition adopting epimedium, glossy privet fruit, radix polygonati officinalis, black soybean, sophora flower, mulberry, raspberry, American ginseng, donkey-hide gelatin, paecilomyces hepialid filament powder as main raw materials in preparing medicaments for treating diminished ovarian reserve and / or promoting endometrial development. The medicinal composition can be used for improving the ovarian reserve function, and promoting endometrial development by improving gynecologic endocrine function and increasing endometrium thickness, and has a wide application prospect.

The invention provides the use of decidual NK cells and cell subgroups in the preparation of drugs for treating infertility-related diseases. It has been confirmed by experiments that the decidual NK cells and their cell subsets can promote endometrial thickness increase, enhance endometrial cell viability, reduce endometrial cell damage, promote VEGF expression, maintain endometrial stromal cell stemness and stimulate proliferation. The method of treating endometrial growth disorder disease can increase the pregnancy success rate of endometrial injury model mice from 30% to 60-70%; The treatment of diseases related to maternal-fetal immune tolerance disorder at the level of lymphocytes provides a new way for the treatment of infertility.